Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome

Journal of Autoimmunity

Volumn 67, Issue , 2016, Pages 102-110

  Cornec, Divi ^a,b   Costa, Sebastian ^c   Devauchelle Pensec, Valérie ^a,b   Jousse Joulin, Sandrine ^a,b   Marcorelles, Pascale ^c   Berthelot, Jean Marie ^d   Chiche, Laurent ^e   Hachulla, Eric ^f   Hatron, Pierre Yves ^f   Goeb, Vincent ^g   Vittecoq, Olivier ^h   Saraux, Alain ^a,b   Pers, Jacques Olivier ^b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b Universite de Brest   (France)

^c CHU MORVAN   (France)

^d HÔTEL DIEU   (France)

^e Unité de médecine interne Hôpital européen   (France)

^f UNIV LILLE   (France)

^g AMIENS UNIVERSITY HOSPITAL   (France)

^h Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

Author keywords

B cells; BAFF; Histology; Primary; Rituximab; Sj gren's syndrome; Treatment efficacy

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PLACEBO; RITUXIMAB; BIOLOGICAL MARKER; IMMUNOLOGIC FACTOR; TNFSF13B PROTEIN, HUMAN;

ADULT; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRY EYE; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MALE; MINOR SALIVA GLAND; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SALIVARY GLAND BIOPSY; SALIVATION; SJOEGREN SYNDROME; T LYMPHOCYTE; TREATMENT RESPONSE; VISUAL ANALOG SCALE; XEROSTOMIA; AGED; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; METABOLISM; MIDDLE AGED; SALIVARY GLAND; SJOGREN'S SYNDROME; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BIOMARKERS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; RITUXIMAB; SALIVARY GLANDS; SJOGREN'S SYNDROME; T-LYMPHOCYTES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84957429265     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.11.002     Document Type: Article

References (55)

1. Cornec D., Devauchelle-Pensec V., Tobón G.J., Pers J.-O., Jousse-Joulin S., Saraux A. B cells in Sjögren's syndrome: From pathophysiology to diagnosis and treatment. J. Autoimmun. 2012, 39:161-167. 10.1016/j.jaut.2012.05.014.
2. Devauchelle-Pensec V., Mariette X., Jousse-Joulin S., Berthelot J.-M., Perdriger A., Puéchal X., et al. Treatment of Primary Sjögren Syndrome With RituximabA Randomized Trial. Ann. Intern. Med. 2014, 160:233-242. 10.7326/M13-1085.
3. Cornec D., Devauchelle-Pensec V., Mariette X., Jousse-Joulin S., Berthelot J.-M., Perdriger A., et al. Development of the Sjögren's Syndrome Responder Index (SSRI), a data-driven composite endpoint for assessing treatment efficacy. Rheumatology (Oxford). 2015 Sep, 54(9):1699-1708. Epub 2015 May 8. 10.1093/rheumatology/kev114.
4. Jousse-Joulin S., Devauchelle-Pensec V., Cornec D., Marhadour T., Bressollette L., Gestin S., et al. Ultrasonographic salivary gland response to rituximab in primary Sjögren's syndrome. Arthritis Rheumatol. 2015 Jun, 67(6):1623-1628. 10.1002/art.39088.
5. Thurlings R.M., Teng O., Vos K., Gerlag D.M., Aarden L., Stapel S.O., et al. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2010, 69:409-412. 10.1136/ard.2009.109041.
6. Bredemeier M., de Oliveira F.K., Rocha C.M. Low-versus high-dose rituximab for Rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res. 2014, 66:228-235. 10.1002/acr.22116.
7. Mariette X., Rouanet S., Sibilia J., Combe B., Loët X.L., Tebib J., et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014 Aug, 73(8):1508-1514. annrheumdis-2013-203480. 10.1136/annrheumdis-2013-203480.
8. Vital E.M., Dass S., Buch M.H., Rawstron A.C., Emery P. An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. Ann Rheum Dis. 2015 Jun, 74(6):1195-1201. annrheumdis-2013-204544. 10.1136/annrheumdis-2013-204544.
9. Guillevin L., Pagnoux C., Karras A., Khouatra C., Aumaître O., Cohen P., et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N. Engl. J. Med. 2014, 371:1771-1780. 10.1056/NEJMoa1404231.
10. Breedveld F., Agarwal S., Yin M., Ren S., Li N.F., Shaw T.M., et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J. Clin. Pharmacol. 2007, 47:1119-1128. 10.1177/0091270007305297.
11. Dass S., Rawstron A.C., Vital E.M., Henshaw K., McGonagle D., Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 2008, 58:2993-2999. 10.1002/art.23902.
12. Specks U., Merkel P.A., Seo P., Spiera R., Langford C.A., Hoffman G.S., et al. Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. N. Engl. J. Med. 2013, 369:417-427. 10.1056/NEJMoa1213277.
13. Cartin-Ceba R., Golbin J.M., Keogh K.A., Peikert T., Sánchez-Menéndez M., Ytterberg S.R., et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum. 2012, 64:3770-3778. 10.1002/art.34584.
14. Calich A.L., Puéchal X., Pugnet G., London J., Terrier B., Charles P., et al. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients. J. Autoimmun. 2014, 50:135-141. 10.1016/j.jaut.2014.03.002.
15. Alberici F., Smith R.M., Jones R.B., Roberts D.M., Willcocks L.C., Chaudhry A., et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2015 Jul, 54(7):1153-1160. 10.1093/rheumatology/keu452.
16. Smith R.M., Jones R.B., Guerry M.-J., Laurino S., Catapano F., Chaudhry A., et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012, 64:3760-3769. 10.1002/art.34583.
17. Yusof M.Y.M., Vital E.M., Das S., Dass S., Arumugakani G., Savic S., et al. Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions. Ann Rheum Dis. 2015 Sep, 74(9):1734-1738. annrheumdis-2014-206496. 10.1136/annrheumdis-2014-206496.
18. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004, 50:2580-2589. 10.1002/art.20430.
19. Anolik J.H., Barnard J., Owen T., Zheng B., Kemshetti S., Looney R.J., et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007, 56:3044-3056. 10.1002/art.22810.
20. Albert D., Dunham J., Khan S., Stansberry J., Kolasinski S., Tsai D., et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann. Rheum. Dis. 2008, 67:1724-1731. 10.1136/ard.2007.083162.
21. Vital E.M., Dass S., Buch M.H., Henshaw K., Pease C.T., Martin M.F., et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011, 63:3038-3047. 10.1002/art.30466.
22. Vos K., Thurlings R.M., Wijbrandts C.A., van Schaardenburg D., Gerlag D.M., Tak P.P. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum. 2007, 56:772-778. 10.1002/art.22400.
23. Thurlings R.M., Vos K., Wijbrandts C.A., Zwinderman A.H., Gerlag D.M., Tak P.P. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann. Rheum. Dis. 2008, 67:917-925. 10.1136/ard.2007.080960.
24. Teng Y.K.O., Levarht E.W.N., Hashemi M., Bajema I.M., Toes R.E.M., Huizinga T.W.J., et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum. 2007, 56:3909-3918. 10.1002/art.22967.
25. Pers J.-O., Devauchelle V., Daridon C., Bendaoud B., Berre R.L., Bordron A., et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of RITUXIMAB-TREATED patients with Sjögren's syndrome. Arthritis Rheum. 2007, 56:1464-1477. 10.1002/art.22603.
26. Carubbi F., Cipriani P., Marrelli A., Benedetto P.D., Ruscitti P., Berardicurti O., et al. Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res. Ther. 2013, 15. R172. 10.1186/ar4359.
27. Pijpe J., Meijer J.M., Bootsma H., van der Wal J.E., Spijkervet F.K.L., Kallenberg C.G.M., et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Arthritis Rheum. 2009, 60:3251-3256. 10.1002/art.24903.
28. Hamza N., Bootsma H., Yuvaraj S., Spijkervet F.K.L., Haacke E.A., Pollard R.P.E., et al. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy. Ann. Rheum. Dis. 2012, 71:1881-1887. 10.1136/annrheumdis-2011-201189.
29. Fairfax K.A., Tsantikos E., Figgett W.A., Vincent F.B., Quah P.S., LePage M., et al. BAFF-driven autoimmunity requires CD19 expression. J. Autoimmun. 2015, 62:1-10. 10.1016/j.jaut.2015.06.001.
30. Youinou P., Pers J.-O. Primary Sjögren's syndrome at a glance today. Joint Bone Spine. 2015 Mar, 82(2):75-76. 10.1016/j.jbspin.2014.10.018.
31. Mariette X., Roux S., Zhang J., Bengoufa D., Lavie F., Zhou T., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann. Rheum. Dis. 2003, 62:168-171.
32. Pers J.-O., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann. N. Y. Acad. Sci. 2005, 1050:34-39. 10.1196/annals.1313.004.
33. d'Arbonneau F., Pers J.-O., Devauchelle V., Pennec Y., Saraux A., Youinou P. BAFF-induced changes in B cell antigen receptor-containing lipid rafts in Sjögren's syndrome. Arthritis Rheum. 2006, 54:115-126. 10.1002/art.21478.
34. Daridon C., Devauchelle V., Hutin P., Le Berre R., Martins-Carvalho C., Bendaoud B., et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum. 2007, 56:1134-1144. 10.1002/art.22458.
35. Ittah M., Miceli-Richard C., J.- Eric Gottenberg, Lavie F., Lazure T., Ba N., et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res. Ther. 2006, 8:R51. 10.1186/ar1912.
36. Lahiri A., Varin M.-M., Le Pottier L., Pochard P., Bendaoud B., Youinou P., et al. Specific forms of BAFF favor BAFF receptor-mediated epithelial cell survival. J. Autoimmun. 2014, 51:30-37. 10.1016/j.jaut.2014.02.004.
37. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 2002, 61:554-558.
38. Costa S., Quintin-Roué I., Lesourd A., Jousse-Joulin S., Berthelot J.-M., Hachulla E., et al. Reliability of histopathological salivary gland biopsy assessment in Sjögren's syndrome: a multicentre cohort study. Rheumatology (Oxford) 2015 Jun, 54(6):1056-1064. 10.1093/rheumatology/keu453.
39. Costa S., Schutz S., Cornec D., Uguen A., Quintin-Roue I., Lesourd A., et al. B and T cells count in minor salivary glands of primary Sjogren's syndrome: development and validation of a digital procedure. Scand. J. Immunol. 2015, 81. 388-388.
40. Cornec D., Tempescul A., Querellou S., Hutin P., Pers J.-O., Jamin C., et al. Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. Ann. Hematol. 2012, 91:715-721. 10.1007/s00277-011-1369-y.
41. Cambridge G., Isenberg D.A., Edwards J.C.W., Leandro M.J., Migone T.-S., Teodorescu M., et al. B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 2008, 67:1011-1016. 10.1136/ard.2007.079418.
42. Navarra S.V., Guzmán R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731. 10.1016/S0140-6736(10)61354-2.
43. Furie R., Petri M., Zamani O., Cervera R., Wallace D.J., Tegzová D., et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011, 63:3918-3930. 10.1002/art.30613.
44. Mariette X., Seror R., Quartuccio L., Baron G., Salvin S., Fabris M., et al. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. Ann. Rheum. Dis. 2015, 74:526-531. 10.1136/annrheumdis-2013-203991.
45. Pontarini E., Fabris M., Quartuccio L., Cappeletti M., Calcaterra F., Roberto A., et al. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome. Rheumatology (Oxford). 2015 Aug, 54(8):1429-1434. 10.1093/rheumatology/kev005.
46. Seror R., Lazure T., Desmoulins F., Pavy S., Miceli-Richard C., Ravaud P., et al. Modification of salivary gland lymphocyte pattern after belimumab in primary Sjogren's syndrome: results of the BELISS study. Ann. Rheum. Dis. 2013, 72(Suppl. 3):89.
47. De Vita S., Quartuccio L., Salvin S., Picco L., Scott C.A., Rupolo M., et al. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. Clin. Exp. Rheumatol. 2014, 32:490-494.
48. Wild J., Schmiedel B.J., Maurer A., Raab S., Prokop L., Stevanović S., et al. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis. Leukemia. 2015 Aug, 29(8):1676-1683. 10.1038/leu.2015.50.
49. Cambridge G., Stohl W., Leandro M.J., Migone T.-S., Hilbert D.M., Edwards J.C.W. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006, 54:723-732. 10.1002/art.21650.
50. Lavie F., Miceli-Richard C., Ittah M., Sellam J., Gottenberg J.-E., Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann. Rheum. Dis. 2007, 66:700-702. 10.1136/ard.2006.060772.
51. Pollard R.P.E., Abdulahad W.H., Vissink A., Hamza N., Burgerhof J.G.M., Meijer J.M., et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: data from a placebo-controlled clinical trial. Ann. Rheum. Dis. 2013, 72:146-148. 10.1136/annrheumdis-2012-202071.
52. Seror R., Sordet C., Guillevin L., Hachulla E., Masson C., Ittah M., et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann. Rheum. Dis. 2007, 66:351-357. 10.1136/ard.2006.057919.
53. Vallerskog T., Heimbürger M., Gunnarsson I., Zhou W., Wahren-Herlenius M., Trollmo C., et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res. Ther. 2006, 8:R167. 10.1186/ar2076.
54. Kraaij T., Huizinga T.W.J., Rabelink T.J., Teng Y.K.O. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatol. Oxf. Engl. 2014, 53:2122-2124. 10.1093/rheumatology/keu369.
55. Fisher B.A., Brown R.M., Bowman S.J., Barone F. A review of salivary gland histopathology in primary Sjögren's syndrome with a focus on its potential as a clinical trials biomarker. Ann Rheum Dis. 2015 Sep, 74(9):1645-1650. annrheumdis-2015-207499. 10.1136/annrheumdis-2015-207499.